Cosmos Health Inc.
Close on Oct 19, 2026
- Market cap
- $19.48M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 16, 2026, after market close (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 20, 2026 | After market close | $18.99M | – | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 22, 2026 | During market hours | $17.93M | – | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 17, 2025 | After market close | $17.11M | $-0.17 | $-0.02 |
| Q3 FY2023 Ended Sep 30, 2023 | Nov 22, 2023 | During market hours | $12.80M | – | – |
| Q2 FY2023 Ended Jun 30, 2023 | Aug 15, 2023 | After market close | $12.36M | – | $0.01 |
| Q1 FY2023 Ended Mar 31, 2023 | Apr 18, 2023 | Before market open | – | – | – |
| Q3 FY2022 Ended Sep 30, 2022 | Nov 16, 2022 | After market close | – | – | – |
| Q2 FY2022 Ended Jun 30, 2022 | Aug 23, 2022 | After market close | – | – | – |
| Q1 FY2022 Ended Mar 31, 2022 | May 18, 2022 | Before market open | – | – | – |
| Q1 FY2021 Ended Mar 31, 2021 | May 18, 2021 | Before market open | – | – | – |
| Q3 FY2020 Ended Sep 30, 2020 | Nov 17, 2020 | After market close | – | – | – |
Press releases
Announcements Cosmos Health filed with the SEC
Cosmos Health Authorizes Up to $5 Million Share Repurchase Program
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Scaled contract manufacturing division , securing long-term agreements for over 12 million units
Results of operations · EX-99.1 to Form 8-K
Cosmos Health Reports Record Q3 2025 Results with All-Time High Revenue, Gross Profit and Gross Margin; Revenue Up 38% to $17.1M, Gross Profit Up 116% to $2.6M, Adjusted EBITDA Up 74%, Cash Position Up to $4.63M from $0.66M
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Cosmos Health Regains Compliance with Nasdaq Minimum Bid Price Requirement
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Cosmos Health CEO Issues Letter to Shareholders: Building a Global Healthcare Powerhouse with $300M Digital Financing Facility, U.S. Manufacturing Expansion, and AI Innovation
Regulation FD disclosure · EX-99.1 to Form 8-K
Cosmos Health Secures up to $300 Million Financing Facility to Launch Ethereum Treasury Strategy
Material agreement · New financial obligation · Unregistered share sale · Other events · EX-99.1 to Form 8-K
Cosmos Health Announces It Will Not Proceed with an Offering Under Its Form S-1
Regulation FD disclosure · EX-99.1 to Form 8-K
Cosmos Health Regains Compliance with Nasdaq Minimum Bid Price Rule
Other events · EX-99.1 to Form 8-K
RELATED PARTY TRANSACTION POLICIES AND PROCEDURES
Listing notice · Other events · EX-99.1 to Form 8-K
Cosmos Health Bolsters Presence in $400Bn+ Global Generic Drugs Market with $3.5M Acquisition of 10-Drug Portfolio
Other events · EX-99.1 to Form 8-K
Cosmos Health Set for Substantial Growth From Acquisitions Completed in 2023
Material agreement · Unregistered share sale · Other events · EX-99.1 to Form 8-K
Cosmos Health Reports Q3 2023 Results; Revenue Increased 7% YoY, Total Assets Reached Record $71.5M with Stockholders' Equity of $44.2M or $3.4/Share
Results of operations · EX-99.1 to Form 8-K
COSMOS HEALTH CEO Issues Letter to Shareholders
Other events · EX-99.1 to Form 8-K
Cosmos Health Ends 2022 with Transformed Balance Sheet and
Results of operations · EX-99.1 to Form 8-K
Cosmos Holdings Inc. Changes its Name to Cosmos Health Inc.
Charter or bylaw amendment · Other events · EX-99.1 to Form 8-K
Cosmos Health Reports Third Quarter 2022 Financial Results
Results of operations · Listing notice · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
Cosmos Health Reports 202.42 % Increase in Adjusted EBITDA and
Results of operations · EX-99.1 to Form 8-K
Cosmos Holdings Announces Name Change to Cosmos Health, Reflecting Company’s
Listing notice · Charter or bylaw amendment · Other events · EX-99.1 to Form 8-K
Cosmos Holdings Reports 12.5% Increase in Revenue, 88.9% Increase in Gross Profit and Achieves Profitability for the First Quarter of 2022
Results of operations · EX-99.1 to Form 8-K
Cosmos Holdings Announces Closing of $6 Million Private Placement of Convertible Preferred Stock and Start of Trading on the Nasdaq
Material agreement · Unregistered share sale · Charter or bylaw amendment · Other events · EX-99.1 to Form 8-K
Cosmos Holdings Announces Shareholder Approval of Private Offering
Regulation FD disclosure · EX-99.1 to Form 8-K
As 'Adjusted Pro Forma (1)
Unregistered share sale · Other events · EX-99.1 to Form 8-K/A
As 'Adjusted Pro Forma (1)
Unregistered share sale · Other events · EX-99.1 to Form 8-K